Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02622334 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A Phase 1 study of Glaucoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT02622334: Completed Phase 1 study of Glaucoma, sponsored by Hoffmann-La Roche.
NCT02622334 is a Phase 1 study of Glaucoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 45 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02622334, a Phase 1 study of Glaucoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Latanoprost
- DRUG RO5093151
Study Locations (7)
California
- Sall Research Medical Center - Artesia
Colorado
- Rocky Mountain Lions Eye Inst - Aurora
Georgia
- Eye Care Centers Management, Inc. (Clayton Eye Center) - Morrow
New York
- New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute - New York
North Carolina
- Cornerstone Eye Care, Div of Cornerstone Health Care - High Point
West Virginia
- West Virginia University Eye Institute - Morgantown
Other
- Singapore National Eye Centre; Glaucoma Department - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-12-29 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 1 |
What the finished NCT02622334 record still lists
NCT02622334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02622334 lists 7 locations in 7 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT02622334 about?
NCT02622334 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).". The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
What is the current status of trial NCT02622334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2015-12-29. Estimated completion is 2016-07-28.
What conditions does trial NCT02622334 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT02622334?
The interventions under investigation include: Placebo (DRUG), Latanoprost (DRUG), RO5093151 (DRUG).
Who is sponsoring clinical trial NCT02622334?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02622334 being conducted?
This trial has 7 study locations across California, Colorado, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02622334's enrollment target sits among peer trials
45 70th of 92 higher than 22 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI